Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Betting Generic: Part D, Patents and Proteins Drive Investment Surge

This article was originally published in RPM Report

Executive Summary

Generic drug companies have been spurned by Wall Street in the past in favor of their brand manufacturing counterparts. With high generic use rates in Medicare Part D and a perceived inevitability of follow-on biologics, investment in pharmaceutical copycats is on the upswing.
Advertisement

Related Content

Big Pharma May Be Big Player in Follow-On Biologics Market
Big Pharma May Be Big Player in Follow-On Biologics Market
Big Pharma May Be Big Player in Follow-On Biologics Market
Big Pharma May Be Big Player in Follow-On Biologics Market
Flubbing the FOBs Opportunity: Follow-on Biologics Winners & Losers
With Enemies Like These: Will the Democrats Make Part D More Pharma Friendly?
The Provenge Precedent
The War on Generics - Part II
The War on Generics - Part I
Biogenerics Are Happening: Slowly, Product-By-Product

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS080337

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel